Abstract
The updosing of second-generation antihistamines for chronic urticaria is based on inconsistent findings. Herein, we report data on the treatment of children with chronic spontaneous urticaria (CSU) unresponsive to single doses of second-generation H(1)-antihistamines in whom an increase in antihistamine was performed without improvement and with a high prevalence of adverse events. Thus, it appears that well-controlled, well-designed clinical trials are needed to clarify which nonsedating antihistamines should be used, in what dose, and for how long in patients not responding to the standard treatment, despite the improvement in health care that guidelines help to incorporate. Furthermore, a critical use of such guidelines should be done to improve the knowledge in CSU, especially in the pediatric population.
References
1.
Zuberbier
T
, Aberer
W
, Asero
R
, Abdul Latiff
AH
, Baker
D
, Ballmer-Weber
B
, et al. The EAACI/GA2LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update
. Allergy
. 2018
.0105-45382.
Fitzsimons
R
, van der Poel
LA
, Thornhill
W
, du Toit
G
, Shah
N
, Brough
HA
. Antihistamine use in children
. Arch Dis Child Educ Pract Ed
. 2015
Jun
;100
(3
):122
–31
.
[PubMed]
1743-05853.
Staevska
M
, Popov
TA
, Kralimarkova
T
, Lazarova
C
, Kraeva
S
, Popova
D
, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria
. J Allergy Clin Immunol
. 2010
Mar
;125
(3
):676
–82
.
[PubMed]
0091-67494.
Manti S, Brown P, Perez MK, Piedimonte G. The role of neurotrophins in inflammation and allergy. Vitam Horm. 2017;104:313–341.
5.
Yanai
K
, Okamura
N
, Tagawa
M
, Itoh
M
, Watanabe
T
. New findings in pharmacological effects induced by antihistamines: from PET studies to knock-out mice
. Clin Exp Allergy
. 1999
Jul
;29
Suppl 3
:29
–36
.
[PubMed]
0954-78946.
Motola
D
, Donati
M
, Biagi
C
, Calamelli
E
, Cipriani
F
, Melis
M
, et al. Safety profile of H1-antihistamines in pediatrics: an analysis based on data from VigiBase
. Pharmacoepidemiol Drug Saf
. 2017
Oct
;26
(10
):1164
–71
.
[PubMed]
1053-85697.
Doshi
DR
, Weinberger
MM
. Experience with cyclosporine in children with chronic idiopathic urticaria
. Pediatr Dermatol
. 2009
Jul-Aug
;26
(4
):409
–13
.
[PubMed]
0736-80468.
Giuliodori
K
, Ganzetti
G
, Campanati
A
, Simonetti
O
, Marconi
B
, Offidani
A
. A non-responsive chronic autoimmune urticaria in a 12-year-old autistic girl treated with cyclosporin
. J Eur Acad Dermatol Venereol
. 2009
May
;23
(5
):619
–20
.
[PubMed]
0926-99599.
Neverman
L
, Weinberger
M
. Treatment of chronic urticaria in children with antihistamines and cyclosporine
. J Allergy Clin Immunol Pract
. 2014
Jul-Aug
;2
(4
):434
–8
.
[PubMed]
2213-219810.
Ben-Shoshan
M
, Grattan
CE
. Management of Pediatric Urticaria with Review of the Literature on Chronic Spontaneous Urticaria in Children
. J Allergy Clin Immunol Pract
. 2018
Jul - Aug
;6
(4
):1152
–61
.
[PubMed]
2213-219811.
Asero
R
. Chronic unremitting urticaria: is the use of antihistamines above the licensed dose effective? A preliminary study of cetirizine at licensed and above-licensed doses
. Clin Exp Dermatol
. 2007
Jan
;32
(1
):34
–8
.
[PubMed]
0307-6938© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
